Table 2 Baseline patient characteristics according to total patients, NLR, dNLR, PLR and LMR level
Characteristics |  | Total patients (n = 389) | Patients grouped by NLR level (n = 389) | P * | Patients grouped by dNLR level (n = 389) | P * | Patients grouped by PLR level (n = 389) | P * | Patients grouped by LMR level (n = 389) | P * | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NLR < 2.36 (n = 132) | NLR ≥ 2.36 (n = 257) | dNLR < 1.85 (n = 151) | dNLR ≥ 1.85 (n = 238) | PLR < 132 (n = 165) | PLR ≥ 132 (n = 224) | LMR < 4.95 (n = 241) | LMR ≥ 4.95 (n = 148) | |||||||
Sex | Female | 107 (27.5%) | 37 (28.0%) | 70 (27.2%) | 0.868 | 41 (27.2%) | 66 (27.7%) | 0.901 | 54 (32.7%) | 53 (23.7%) | 0.048 | 59 (24.5%) | 48 (32.4%) | 0.088 |
Male | 282 (72.5%) | 95 (72.0%) | 187 (72.8%) | 110 (72.8%) | 172 (72.3%) | 111 (67.3%) | 171 (76.3%) | 182 (75.5%) | 100 (67.6%) | |||||
Age (years) | <65 | 185 (47.6%) | 74 (56.1%) | 111 (43.2%) | 0.016 | 83 (55.0%) | 102 (42.9%) | 0.020 | 87 (52.7%) | 98 (43.8%) | 0.080 | 98 (40.7%) | 87 (58.8%) | 0.001 |
≥65 | 204 (52.4%) | 58 (43.9%) | 146 (56.8%) | 68 (45.0%) | 136 (57.1%) | 78 (47.3%) | 126 (56.2%) | 143 (59.3%) | 61 (41.2%) | |||||
Alcohol | Yes | 73 (18.8%) | 31 (23.5%) | 42 (16.3%) | 0.088 | 32 (21.2%) | 41 (17.2%) | 0.329 | 36 (21.8%) | 37 (16.5%) | 0.186 | 44 (18.3%) | 29 (19.6%) | 0.743 |
No | 316 (81.2%) | 101 (76.5%) | 215 (83.7%) | 119 (78.8%) | 197 (82.8%) | 129 (78.2%) | 187 (83.5%) | 197 (81.7%) | 119 (80.4%) | |||||
Tobacco | Yes | 72 (18.5%) | 29 (22.0%) | 43 (16.7%) | 0.208 | 30 (19.9%) | 42 (17.6%) | 0.583 | 37 (22.4%) | 35 (15.6%) | 0.088 | 46 (19.1%) | 26 (17.6%) | 0.708 |
No | 317 (81.5%) | 103 (78.0%) | 214 (83.3%) | 121 (80.1%) | 196 (82.4%) | 128 (77.6%) | 189 (84.4%) | 195 (80.9%) | 122 (82.4%) | |||||
Family history | Yes | 15 (3.9%) | 4 (3.0%) | 11 (4.3%) | 0.544 | 5 (3.3%) | 10 (4.2%) | 0.657 | 9 (5.5%) | 6 (2.7%) | 0.160 | 6 (2.5%) | 9 (6.1%) | 0.100 |
No | 374 (96.1%) | 128 (97.0%) | 246 (95.7%) | 146 (96.7%) | 228 (95.8%) | 156 (94.5%) | 218 (97.3%) | 235 (97.5%) | 139 (93.9%) | |||||
Histological type | papillary | 19 (4.9%) | 8 (6.1%) | 11 (4.3%) | 0.543 | 10 (6.7%) | 9 (3.8%) | 0.424 | 15 (9.1%) | 4 (1.8%) | 0.009 | 9 (3.7%) | 10 (6.8%) | 0.260 |
tubular | 81 (20.8%) | 26 (19.7%) | 55 (21.4%) | 32 (21.1%) | 49 (20.6%) | 30 (18.2%) | 51 (22.8%) | 45 (18.7%) | 36 (24.3%) | |||||
   poorly differentiated | 203 (52.2%) | 66 (50.0%) | 137 (53.3%) | 74 (49.0%) | 129 (54.2%) | 79 (47.9%) | 124 (55.4%) | 135 (56.0%) | 68 (45.9%) | |||||
| Â | mucinous | 57 (14.7%) | 24 (18.1%) | 33 (12.8%) | 26 (17.2%) | 31 (13.0%) | 28 (16.9%) | 29 (12.9%) | 33 (13.7%) | 24 (16.2%) | ||||
   signetring cell | 29 (7.4%) | 8 (6.1%) | 21 (8.2%) | 9 (6.0%) | 20 (8.4%) | 13 (7.9%) | 16 (7.1%) | 18 (7.5%) | 11 (7.4%) | |||||
Tumor grade | G1-G2 | 214 (55.0%) | 68 (51.5%) | 146 (56.8%) | 0.320 | 78 (51.7%) | 136 (58.0%) | 0.289 | 85 (51.5%) | 129 (57.6%) | 0.234 | 133 (55.2%) | 81 (54.7%) | 0.930 |
G3-G4 | 175 (45.0%) | 64 (48.5%) | 111 (43.2%) | 73 (48.3%) | 102 (42.0%) | 80 (48.5%) | 95 (42.4%) | 108 (44.8%) | 67 (45.3%) | |||||
Tumor stage | I-II | 159 (40.9%) | 95 (72.0%) | 64 (24.9%) | 0.000 | 78 (51.7%) | 81 (34.0%) | 0.001 | 83 (50.3%) | 76 (33.9%) | 0.001 | 72 (29.9%) | 87 (58.8%) | 0.000 |
III-IV | 230 (59.1%) | 37 (28.0%) | 193 (75.1%) | 73 (48.3%) | 157 (66.0%) | 82 (49.7%) | 148 (66.1%) | 169 (70.1%) | 61 (41.2%) | |||||
Depth of invasion | T1-T2 | 66 (17.0%) | 38 (28.8%) | 28 (10.9%) | 0.000 | 37 (24.5%) | 29 (12.2%) | 0.002 | 44 (26.7%) | 22 (9.8%) | 0.000 | 22 (9.1%) | 44 (29.7%) | 0.000 |
T3-T4 | 323 (83%) | 94 (71.2%) | 229 (89.1%) | 114 (75.5%) | 209 (87.8%) | 121 (73.3%) | 202 (90.2%) | 219 (90.9%) | 104 (70.3%) | |||||
Lymph node | N0 | 72 (18.5%) | 41 (31.1%) | 31 (12.1%) | 0.000 | 42 (27.8%) | 30 (12.6%) | 0.000 | 43 (26.1%) | 29 (12.9%) | 0.000 | 27 (11.2%) | 45 (30.4%) | 0.000 |
N1-N3 | 317 (81.5%) | 91 (68.9%) | 226 (87.9%) | 109 (72.2%) | 208 (87.4%) | 122 (73.9%) | 195 (87.1%) | 214 (88.8%) | 103 (69.6%) | |||||
Distant metastasis | M0 | 235 (60.4%) | 106 (80.3%) | 129 (50.2%) | 0.000 | 116 (76.8%) | 119 (50.0%) | 0.000 | 116 (70.3%) | 119 (53.1%) | 0.001 | 119 (49.4%) | 116 (78.4%) | 0.000 |
M1 | 154 (39.6%) | 26 (19.7%) | 128 (49.8%) | 35 (23.2%) | 119 (50.0%) | 49 (29.7%) | 105 (46.9%) | 122 (50.6%) | 32 (21.6%) | |||||
CEA (ng/ml) | ≤5 | 243 (62.5%) | 92 (69.7%) | 151 (58.8%) | 0.034 | 107 (70.9%) | 136 (57.1%) | 0.006 | 113 (68.5%) | 130 (58.0%) | 0.035 | 134 (55.6%) | 109 (73.6%) | 0.000 |
>5 | 146 (37.5%) | 40 (30.3%) | 106 (41.2%) | 44 (29.1%) | 102 (42.9%) | 52 (31.5%) | 94 (42.0%) | 107 (44.4%) | 39 (26.4%) | |||||
CA199 (U/ml) | ≤37 | 278 (71.5%) | 109 (82.6%) | 169 (65.8%) | 0.001 | 123 (81.5%) | 155 (65.1%) | 0.001 | 130 (78.8%) | 148 (66.1%) | 0.006 | 160 (66.4%) | 118 (79.7%) | 0.005 |
>37 | 111 (28.5%) | 23 (17.4%) | 88 (34.2%) | 28 (18.5%) | 83 (34.9%) | 35 (21.2%) | 76 (33.9%) | 81 (33.6%) | 30 (20.3%) | |||||